Finance

Lists
Outlook: 6.7% bullish·80.0% bearish
Go to analysis
ZURA:NASDAQ
Zura Bio Ltd
US$ १.४३
+१.७८%
(+०.०२५) 1D
US$ १.४०
-२.१०% (-०.०३०)
After hours
Closed: नोभेम्बर ११, १६:००:०१ GMT-५  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZURA...
Open
US$ १.४०
High
US$ १.५८
Low
US$ १.३५
Mkt. cap
१३.७७ करोड
Avg. vol.
६७.९९ लाख
Volume
०.००
52-wk high
US$ ७.४४
52-wk low
US$ ०.९३
EPS
-US$ १.११
Beta
०.०३
Shares outstanding
९.६३ करोड
No. of employees
४०
Open
US$ १.४०
High
US$ १.५८
Low
US$ १.३५
Mkt. cap
१३.७७ करोड
Avg. vol.
६७.९९ लाख
Volume
०.००
52-wk high
US$ ७.४४
52-wk low
US$ ०.९३
EPS
-US$ १.११
Beta
०.०३
Shares outstanding
९.६३ करोड
No. of employees
४०
News stories
From web sources and news partners
About Zura Bio Ltd
CEO-
Employees४०
Founded२०२२
Headquarters-
SectorHealth Care
Industry-
Websitezurabio.com
Analyst ratings
Based on 6 analysts giving stock ratings to ZURA in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for ZURA in the last 3 months.
Highest
Current US$ १.४३
US$ २६.०० (+१,७१८.१८%)
Average
US$ १०.६७ (+६४६.१५%)
Lowest
US$ ५.०० (+२४९.६५%)
Analyst
Recommendation
Action
Price target
Projected
Date
Kaveri Pohlman
Clear Street
Buy
Maintained
US$ १०.००
+५९९.३%
11/10/2026
Justin Kim
Oppenheimer
Buy
Maintained
US$ ५.००
+२४९.७%
11/10/2026
Yatin Suneja
Guggenheim
Buy
Maintained
US$ ८.००
+४५९.४%
11/10/2026
Thomas Smith
Leerink Partners
Buy
Maintained
US$ ५.००
+२४९.७%
11/09/2026
Martin Fan
Wedbush
Buy
Reiterated
US$ १०.००
+५९९.३%
11/09/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
US$ २६.००
+१,७१८.२%
10/07/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
US$ ११.००
+६६९.२%
10/02/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
US$ २०.००
+१,२९८.६%
10/02/2026
Matt Phipps
William Blair
Buy
Reiterated
-
-
08/11/2026
Daniil Gataulin
Chardan Capital
Buy
Reiterated
US$ ११.००
+६६९.२%
05/07/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
२०२६ सेप्टेम्बर
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
१.१० करोड
१.४७ करोड
२.०७ करोड
१.९५ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
७४.५५ लाख
१.०८ करोड
८६.१५ लाख
९२.८२ लाख
Operating expense
१.८४ करोड
२.५५ करोड
२.९३ करोड
२.८८ करोड
Total operating expenses
१.८४ करोड
२.५५ करोड
२.९३ करोड
२.८८ करोड
Operating income
-१.८४ करोड
-२.५५ करोड
-२.९३ करोड
-२.८८ करोड
Other non operating income
-४०.०० हजार
-४३.०० हजार
१०.१६ लाख
-३२.०० हजार
EBT including unusual items
-१.७२ करोड
-२.४२ करोड
-२.६४ करोड
-२.७० करोड
EBT excluding unusual items
-१.७२ करोड
-२.४२ करोड
-२.६४ करोड
-२.७० करोड
Income tax expense
-
-
-८१.०० हजार
-१२.२१ लाख
Effective tax rate
-
-
०.३१%
४.५१%
Other operating expenses
-
-
-
-
Net income
-१.७२ करोड
-२.४२ करोड
-२.६३ करोड
-२.५८ करोड
Net profit margin
-
-
-
-
Earnings per share
-०.४९
-०.२२
-०.२१
-०.२०
Interest and investment income
१२.७६ लाख
१३.१९ लाख
१९.२० लाख
१७.५९ लाख
Interest expense
-
-
-
-
Net interest expenses
१२.७६ लाख
१३.१९ लाख
१९.२० लाख
१७.५९ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-१.८४ करोड
-२.५५ करोड
-२.९३ करोड
-२.८८ करोड
Gain or loss from assets sale
-
३.०० हजार
२.०० हजार
१.०० हजार
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू